Caring for children with drug-resistant tuberculosis: Practice-based recommendations

American Journal of Respiratory and Critical Care Medicine

Volumn 186, Issue 10, 2012, Pages 953-964

  Seddon, James A ^a,b   Furin, Jennifer J ^c   Gale, Marianne ^d   Del Castillo Barrientos, Hernan ^e,f   Hurtado, Rocío M ^g,h,i   Amanullah, Farhana ^j   Ford, Nathan ^d   Starke, Jeffrey R ^k   Schaaf, H Simon ^a,l  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MÉDECINS SANS FRONTIÈRES   (Switzerland)

^e INSTITUTO NACIONAL DE SALUD DEL NIÑO   (Peru)

^f Unión Nacional Contra La Tuberculosis   (Peru)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h Global Health Committee   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j THE INDUS HOSPITAL   (Pakistan)

^k BAYLOR COLLEGE OF MEDICINE   (United States)

^l STELLENBOSCH UNIVERSITY   (South Africa)

more..

Author keywords

Child; Drug resistance; Pediatrics

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TERIZIDONE; THIOACETAZONE;

ABDOMINAL PAIN; ADVERSE OUTCOME; ALLERGIC REACTION; ARTHRITIS; BONE MARROW SUPPRESSION; BRONCHUS BIOPSY; CHILD CARE; COMORBIDITY; DIARRHEA; DISEASE COURSE; DISEASE TRANSMISSION; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG RESISTANT TUBERCULOSIS; GASTROINTESTINAL SYMPTOM; HEARING IMPAIRMENT; HEART VENTRICLE ARRHYTHMIA; HEPATITIS; HUMAN; HYPOTHYROIDISM; INFECTION CONTROL; KIDNEY DYSFUNCTION; LACTIC ACIDOSIS; LIVER DYSFUNCTION; LUNG BIOPSY; LUNG LAVAGE; MENTAL DISEASE; MORBIDITY; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROTOXICITY; OPTIC NERVE DISEASE; OPTIC NEURITIS; OTOTOXICITY; PANCREATITIS; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SEIZURE; SKIN DISCOLORATION; SKIN MANIFESTATION; SLEEP DISORDER; SPUTUM DISCOLORATION; STEVENS JOHNSON SYNDROME; TASTE DISORDER; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL IMPAIRMENT; VOMITING; XEROSIS;

ANTITUBERCULAR AGENTS; CHILD; DIRECTLY OBSERVED THERAPY; DRUG MONITORING; HUMANS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84869219630     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201206-1001CI     Document Type: Review

References (122)

1. World Health Organization Global tuberculosis control. WHO/HTM/TB/2011.16. Geneva, Switzerland: WHO; 2011.
2. World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children. WHO/HTM/TB/2006.371, WHO/FCH/CAH/2006.7. Geneva, Switzerland: WHO; 2006.
3. van Rie A, Beyers N, Gie RP, Kunneke M, Zietsman L, Donald PR. Childhood tuberculosis in an urban population in South Africa: burden and risk factor. Arch Dis Child 1999;80:433-437. (Pubitemid 29220178)
4. Marais BJ, Hesseling AC, Gie RP, Schaaf HS, Beyers N. The burden of childhood tuberculosis and the accuracy of community-based surveillance data. Int J Tuberc Lung Dis 2006;10:259-263.
5. Ettehad D, Schaaf HS, Seddon JA, Cooke GS, Ford N. Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012;12:449-456.
6. Nicol MP, Zar HJ. New specimens and laboratory diagnostics for childhood pulmonary TB: progress and prospects. Paediatr Respir Rev 2011;12:16-21.
7. World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. Policy statement. 2011 [accessed 2012 Aug 31]. Available from: http://whqlibdoc.Who.Int/publications/2011/9789241501545-eng. Pdf
8. World Health Organization. Molecular line probe assays for the rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB). Policy statement. 2008 [accessed 2012 Aug 31]. Available from: http://www.who.int/tb/features-archive/policy-statement.pdf.
9. Partners in Health. The partners in health guide to the medical management of multidrug-resistant tuberculosis. Boston, MA: Partners in Health; 2003.
10. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update. WHO/HTM/TB/2008.402. 2008 [accessed 2012 Aug 31]. Available from: http://whqlibdoc.who.int/publications/ 2008/9789241547581-eng.pdf
11. Holdiness MR. Clinical pharmacokinetics of the antituberculosis drugs. Clin Pharmacokinet 1984;9:511-544. (Pubitemid 15211649)
12. Dubo S. Psychiatric study of children with pulmonary tuberculosis. Am J Orthopsychiatry 1950;20:520-528.
13. Schaaf HS, Marais BJ. Management of multidrug-resistant tuberculosis in children: a survival guide for paediatricians. Paediatr Respir Rev 2011;12:31-38.
14. Al-Dabbagh M, Lapphra K,McGloin R, Inrig K, Schaaf HS,Marais BJ, Sauve L, Kitai I, Kollmann TR. Drug-resistant tuberculosis: pediatric guidelines. Pediatr Infect Dis J 2011;30:501-505.
15. Smith KC, Seaworth BJ. Drug-resistant tuberculosis: controversies and challenges in pediatrics. Expert Rev Anti Infect Ther 2005;3:995-1010. (Pubitemid 41782599)
16. Seddon JA, Godfrey-Faussett P, Hesseling AC, Gie RP, Beyers N, Schaaf HS. Management of children exposed to multidrug-resistant mycobacterium tuberculosis. Lancet Infect Dis 2012;12:469-479.
17. Seddon JA, Hesseling AC, Marais BJ, McIlleron H, Peloquin CA, Donald PR, Schaaf HS. Paediatric use of second-line anti-tuberculosis agents: a review. Tuberculosis (Edinb) 2012;92:9-17.
18. The Sentinel Project on Pediatric Drug-Resistant Tuberculosis [accessed 2012 Mar 22]. Available from: www.sentinel-project.org
19. Feja K, McNelley E, Tran CS, Burzynski J, Saiman L. Management of pediatric multidrug-resistant tuberculosis and latent tuberculosis infections in New York City from 1995 to 2003. Pediatr Infect Dis J 2008;27:907-912.
20. Satti H, McLaughlin MM, Omotayo DB, Keshavjee S, Becerra MC, Mukherjee JS, Seung KJ. Outcomes of comprehensive care for children empirically treated for multidrug-resistant tuberculosis in a setting of high HIV prevalence. PLoS ONE 2012;7:e37114.
21. Schaaf HS, Shean K, Donald PR. Culture-confirmed multidrug-resistant tuberculosis: diagnostic delay, clinical features, and outcome. Arch Dis Child 2003;88:1106-1111.
22. Fairlie L, Beylis NC, Reubenson G, Moore DP, Madhi SA. High prevalence of childhood multi-drug resistant tuberculosis in Johannesburg, South Africa: a cross sectional study. BMC Infect Dis 2011;11:28.
23. Seddon JA, Hesseling AC, Willemse M, Donald PR, Schaaf HS. Culture-confirmed multidrug-resistant tuberculosis in children: clinical features, treatment, and outcome. Clin Infect Dis 2012;54:157-166.
24. Padayatchi N, Bamber S, Dawood H, Bobat R. Multidrug-resistant tuberculous meningitis in children in Durban, South Africa. Pediatr Infect Dis J 2006;25:147-150. (Pubitemid 43208569)
25. Schluger NW, Lawrence RM, McGuiness G, Park M, Rom WN. Multidrug-resistant tuberculosis in children: two cases and a review of the literature. Pediatr Pulmonol 1996;21:138-142. (Pubitemid 26098519)
26. Suessmuth S, Bange FC, Gappa M. Multidrug resistant tuberculosis in a 6 year old child. Paediatr Respir Rev 2007;8:265-268. (Pubitemid 47440670)
27. Kjollerstrom P, Brito MJ, Gouveia C, Ferreira G, Varandas L. Linezolid in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis in paediatric patients: experience of a paediatric infectious diseases unit. Scand J Infect Dis 2011;43:556-559.
28. Rose PC, Hallbauer UM, Seddon JA, Hesseling AC, Schaaf HS. Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children. Int J Tuberc Lung Dis (In press)
29. Zar HJ, Hanslo D, Apolles P, Swingler G, Hussey G. Induced sputum versus gastric lavage for microbiological confirmation of pulmonary tuberculosis in infants and young children: a prospective study. Lancet 2005;365:130-134. (Pubitemid 40091802)
30. Wright CA, Hesseling AC, Bamford C, Burgess SM, Warren R, Marais BJ. Fine-needle aspiration biopsy: a first-line diagnostic procedure in paediatric tuberculosis suspects with peripheral lymphadenopathy? Int J Tuberc Lung Dis 2009;13:1373-1379.
31. Oberhelman RA, Soto-Castellares G, Gilman RH, Caviedes L, Castillo ME, Kolevic L, Del Pino T, Saito M, Salazar-Lindo E, Negron E, et al. Diagnostic approaches for paediatric tuberculosis by use of different specimen types, culture methods, and PCR: a prospective case-control study. Lancet Infect Dis 2010;10:612-620.
32. Zar HJ, Workman L, Isaacs W, Munro J, Black F, Eley B, Allen V, Boehme CC, Zemanay W, Nicol MP. Rapid molecular diagnosis of pulmonary tuberculosis in children using nasopharyngeal specimens. Clin Infect Dis 2012;55:1088-1095.
33. Marais BJ, Hesseling AC, Gie RP, Schaaf HS, Enarson DA, Beyers N. The bacteriologic yield in children with intrathoracic tuberculosis. Clin Infect Dis 2006;42:e69-e71.
34. Goussard P, Gie RP, Kling S, Nel ED, Louw M, Schubert PT, Rhode D, Vanker A, Andronikou S. The diagnostic value and safety of transbronchial needle aspiration biopsy in children with mediastinal lymphadenopathy. Pediatr Pulmonol 2010;45:1173-1179.
35. Drobac PC, Mukherjee JS, Joseph JK, Mitnick C, Furin JJ, del Castillo H, Shin SS, Becerra MC. Community-based therapy for children with multidrug-resistant tuberculosis. Pediatrics 2006;117:2022-2029. (Pubitemid 46071247)
36. Mendez Echevarria A, Baquero Artigao F, Garcia Miguel MJ, Rojo Conejo P, Ballesteros Diez Y, Rubio Gribble B, Garcia Rodriguez J, Del Castillo Martin F. Multidrug-resistant tuberculosis in the pediatric age group. An Pediatr (Barc) 2007;67:206-211. (Pubitemid 47394852)
37. Swanson DS, Starke JR. Drug-resistant tuberculosis in pediatrics. Pediatr Clin North Am 1995;42:553-581.
38. American Academy of Pediatrics. Tuberculosis. In: Pickering LK, ed. Red book: report of the committee on infectious diseases. 28th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2009. pp. 680-701.
39. Ren Y, Nuttall JJ, Egbers C, Eley BS, Meyers TM, Smith PJ, Maartens G, McIlleron HM. Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr 2008;47:566-569. (Pubitemid 351442016)
40. Louw GE, Warren RM, Gey van Pittius NC, Leon R, Jimenez A, Hernandez-Pando R, McEvoy CR, Grobbelaar M, Murray M, van Helden PD, et al. Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant mycobacterium tuberculosis through efflux. Am J Respir Crit Care Med 2011;184:269-276.
41. Weiner M, Burman W, Luo CC, Peloquin CA, Engle M, Goldberg S, Agarwal V, Vernon A. Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrob Agents Chemother 2007;51:2861-2866. (Pubitemid 47206223)
42. Drug-resistant tuberculosis: a survival guide for clinicians, 2nd ed. San Francisco, CA: Curry International Tuberculosis Center; 2008.
43. Frydenberg AR, Graham SM. Toxicity of first-line drugs for treatment of tuberculosis in children. Trop Med Int Health 2009;14:1329-1337.
44. Schaaf HS, Victor TC, Venter A, Brittle W, Jordaan AM, Hesseling AC, Marais BJ, van Helden PD, Donald PR. Ethionamide cross- and co-resistance in children with isoniazid-resistant tuberculosis. Int J Tuberc Lung Dis 2009;13:1355-1359.
45. Schaaf HS, Victor TC, Engelke E, Brittle W, Marais BJ, Hesseling AC, van Helden PD, Donald PR. Minimal inhibitory concentration of isoniazid in isoniazid-resistant mycobacterium tuberculosis isolates from children. Eur J Clin Microbiol Infect Dis 2007;26:203-205.
46. Muller B, Streicher EM, Hoek KG, Tait M, Trollip A, Bosman ME, Coetzee GJ, Chabula-Nxiweni EM, Hoosain E, Gey van Pittius NC, et al. Inha promoter mutations: a gateway to extensively drug-resistant tuberculosis in South Africa? Int J Tuberc Lung Dis 2011;15:344-351.
47. Johnson R, Streicher EM, Louw GE, Warren RM, van Helden PD, Victor TC. Drug resistance in mycobacterium tuberculosis. Curr Issues Mol Biol 2006;8:97-111.
48. Sandgren A, Strong M, Muthukrishnan P, Weiner BK, Church GM, Murray MB. Tuberculosis drug resistance mutation database. PLoS Med 2009;6:e2.
49. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS ONE 2009;4:e6914.
50. Hu Y, CoatesAR,Mitchison DA. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of mycobacterium tuberculosis. Antimicrob Agents Chemother 2003;47:653-657. (Pubitemid 36158096)
51. Handbook of anti-tuberculosis agents. Tuberculosis (Edinb) 2008;88:1-169.
52. Rodriguez JC, Cebrian L, Lopez M, Ruiz M, Jimenez I, Royo G. Mutant prevention concentration: comparison of fluoroquinolones and linezolid with mycobacterium tuberculosis. J Antimicrob Chemother 2004;53:441-444. (Pubitemid 38380240)
53. Cox H, Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis 2012;16:447-454.
54. Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, Rieder HL. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010;182:684-692.
55. Pinon M, Scolfaro C, Bignamini E, Cordola G, Esposito I, Milano R, Mignone F, Bertaina C, Tovo PA. Two pediatric cases of multidrug-resistant tuberculosis treated with linezolid and moxifloxacin. Pediatrics 2010;126:e1253-e1256.
56. Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, Gao M, Awad M, Park SK, Shim TS, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012;366:2151-2160.
57. Diacon AH, Dawson R, du Bois J, Narunsky K, Venter A, Donald PR, van Niekerk C, Erondu N, Ginsberg AM, Becker P, et al. Phase ii dose-ranging trial of the early bactericidal activity of PA-824. Antimicrob Agents Chemother 2012;56:3027-3031.
58. Diacon AH, Donald PR, Pym A, Grobusch M, Patientia RF, Mahanyele R, Bantubani N, Narasimooloo R, De Marez T, van Heeswijk R, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 2012;56:3271-3276.
59. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. WHO/HTM/TB/2011.6. WHO, Geneva, Switzerland.
60. Leimane V, Ozere I. Challenges of managing a child with MDR-TB. 41st World Conference On Lung Health of the International Union Against Tuberculosis and Lung Disease (The Union), Cancun, Mexico, December 3-7, 2009.
61. Thomas TA, Shenoi SV, Heysell SK, Eksteen FJ, Sunkari VB, Gandhi NR, Friedland G, Shah NS. Extensively drug-resistant tuberculosis in children with human immunodeficiency virus in rural South Africa. Int J Tuberc Lung Dis 2010;14:1244-1251.
62. Schaaf HS, Seddon JA, Caminero JA. Second-line antituberclosis drugs: current knowledge and controversies. Progr Respir Res 2011;40:81-95.
63. Steiner P, Rao M, Victoria M, Steiner M. Primary isoniazid-resistant tuberculosis in children: clinical features, strain resistance, treatment, and outcome in 26 children treated at kings county medical center of Brooklyn between the years 1961 and 1972. Am Rev Respir Dis 1974;110:306-311.
64. Dramowski A, Morsheimer MM, Jordaan AM, Victor TC, Donald PR, Schaaf HS. Rifampicin-monoresistant mycobacterium tuberculosis disease among children in Cape Town, South Africa. Int J Tuberc Lung Dis 2012;16:76-81.
65. Hazbon MH, Brimacombe M, Bobadilla del Valle M, Cavatore M, Guerrero MI, Varma-Basil M, Billman-Jacobe H, Lavender C, Fyfe J, Garcia-Garcia L, et al. Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant mycobacterium tuberculosis. Antimicrob Agents Chemother 2006;50:2640-2649. (Pubitemid 44198682)
66. Cilliers K, Labadarios D, Schaaf HS, Willemse M, Maritz JS, Werely CJ, Hussey G, Donald PR. Pyridoxal-5-phosphate plasma concentrations in children receiving tuberculosis chemotherapy including isoniazid. Acta Paediatr 2010;99:705-710.
67. Thwaites G, Fisher M, Hemingway C, Scott G, Solomon T, Innes J. British infection society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. J Infect 2009;59:167-187.
68. Prasad K, Singh MB. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev 2008;CD002244.
69. Schoeman JF, Van Zyl LE, Laubscher JA, Donald PR. Effect of corticosteroids on intracranial pressure, computed tomographic findings, and clinical outcome in young children with tuberculous meningitis. Pediatrics 1997;99:226-231. (Pubitemid 27148875)
70. Goussard P, Gie R. Airway involvement in pulmonary tuberculosis. Paediatr Respir Rev 2007;8:118-123. (Pubitemid 46888356)
71. du Plessis J, Goussard P, Andronikou S, Gie R, George R. Comparing three-dimensional volume-rendered CT images with fibreoptic tracheobronchoscopy in the evaluation of airway compression caused by tuberculous lymphadenopathy in children. Pediatr Radiol 2009;39:694-702.
72. Maydell A, Goussard P, Andronikou S, Bezuidenhout F, Ackermann C, Gie R. Radiological changes post-lymph node enucleation for airway obstruction in children with pulmonary tuberculosis. Eur J Cardiothorac Surg 2010;38:478-483.
73. Hesseling AC, Cotton MF, Jennings T,Whitelaw A, Johnson LF, Eley B, Roux P, Godfrey-Faussett P, Schaaf HS. High incidence of tuberculosis among HIV-infected infants: evidence from a South African population-based study highlights the need for improved tuberculosis control strategies. Clin Infect Dis 2009;48:108-114.
74. Webb EA, Hesseling AC, Schaaf HS, Gie RP, Lombard CJ, Spitaels A, Delport S, Marais BJ, Donald K, Hindmarsh P, et al. High prevalence of mycobacterium tuberculosis infection and disease in children and adolescents with type 1 diabetes mellitus. Int J Tuberc Lung Dis 2009;13:868-874.
75. Singh M, Mynak ML, Kumar L, Mathew JL, Jindal SK. Prevalence and risk factors for transmission of infection among children in household contact with adults having pulmonary tuberculosis. Arch Dis Child 2005;90:624-628. (Pubitemid 40780726)
76. Coyne KM, Pozniak AL, Lamorde M, Boffito M. Pharmacology of second-line antituberculosis drugs and potential for interactions with antiretroviral agents. AIDS 2009;23:437-446.
77. Scano F, Vitoria M, Burman W, Harries AD, Gilks CF, Havlir D. Management of HIV-infected patients with MDR- and XDR-TB in resource-limited settings. Int J Tuberc Lung Dis 2008;12:1370-1375.
78. World Health Organization. Antiretroviral therapy for HIV infection in infants and children: towards universal access. Recommendations for a public health approach. Geneva, Switzerland: WHO; 2010.
79. Department of Health. Republic of South Africa. Management of drug-resistant tuberculosis: policy guidelines [ accessed 2012 Jul 17]. Available from: http://www.Doh.Gov.Za/docs/policy/2011/policy-tb.pdf
80. Torok ME, Yen NT, Chau TT, Mai NT, Phu NH, Mai PP, Dung NT, Chau NV, Bang ND, Tien NA, et al Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculous meningitis. Clin Infect Dis 2011;52:1374-1383.
81. International Network of the Study of HIV-associated IRIS. Case definition: consensus criteria for diagnosis of paediatric TB IRIS. 2008 [accessed 2011 May 29]. Available from: http://www.Inshi.Umn.Edu/definitions/ peds-tb-iris/home.html
82. Boulware DR, Callens S, Pahwa S. Pediatric HIV immune reconstitution inflammatory syndrome. Curr Opin HIV AIDS 2008;3:461-467.
83. Zampoli M, Kilborn T, Eley B. Tuberculosis during early antiretroviral-induced immune reconstitution in HIV-infected children. Int J Tuberc Lung Dis 2007;11:417-423. (Pubitemid 46595772)
84. Collins S, Dent N, Binns P, Bahwere P, Sadler K, Hallam A. Management of severe acute malnutrition in children. Lancet 2006;368:1992-2000. (Pubitemid 44821358)
85. Pawar UM, Kundnani V, Agashe V, Nene A. Multidrug-resistant tuberculosis of the spine-is it the beginning of the end? a study of twenty-five culture proven multidrug-resistant tuberculosis spine patients. Spine 2009;34:E806-E810.
86. Seddon JA, Donald PR, Vlok GJ, Schaaf HS. Multidrug-resistant tuberculosis of the spine in children: characteristics from a high burden setting. J Trop Pediatr 2012;58:341-347.
87. Seddon JA, Visser DH, Bartens M, Jordaan AM, Victor TC, van Furth AM, Schoeman JF, Schaaf HS. Impact of drug resistance on clinical outcome in children with tuberculous meningitis. Pediatr Infect Dis J 2012;31:711-716.
88. McCracken GH Jr. Aminoglycoside toxicity in infants and children. Am J Med 1986;80:172-178.
89. Stelmachowicz PG, Pittman AL, Hoover BM, Lewis DE, Moeller MP. The importance of high-frequency audibility in the speech and language development of children with hearing loss. Arch Otolaryngol Head Neck Surg 2004;130:556-562. (Pubitemid 38609664)
90. Livingstone N, McPhillips M. Motor skill deficits in children with partial hearing. Dev Med Child Neurol 2011;53:836-842.
91. Seddon JA, Godfrey-Faussett P, Jacobs K, Ebrahim A, Hesseling AC, Schaaf HS. Hearing loss in patients on treatment for drug-resistant tuberculosis. Eur Respir J (In press)
92. Seddon JA, Thee S, Hesseling AC, Schaaf HS. Hearing and renal impairment in children treated for drug-resistant tuberculosis [abstract]. 43rd Union World Conference on Lung Health, Kuala Lumpur, Malaysia, November 13-17, 2012.
93. World Health Organization. WHO child growth standards and the identification of severe acute malnutrition in infants and children: a joint statement by the World Health Organization and the United Nations Children's Fund [accessed 2012 Jul 11]. Available from: http://www.Who.Int/nutrition/ publications/severemalnutrition/9789241598163-eng.pdf
94. American Speech-Language-Hearing Association. Audiologic management of inidividuals receiving cochleotoxic drug therapy (guideline) [accessed 2012 Aug 31]. Available from: http://www.asha.org/docs/pdf/GL1994-00003.pdf
95. World Health Organization. Ethambutol efficacy and toxicity: Literature review and recommendations for daily and intermittent dosage in children. WHO/HTM/TB/2006365; WHO/FCH/CAH/20063. Geneva, Switzerland: WHO; 2006.
96. Donald PR, Maher D, Maritz JS, Qazi S. Ethambutol dosage for the treatment of children: literature review and recommendations. Int J Tuberc Lung Dis 2006;10:1318-1330. (Pubitemid 44929444)
97. Thee S, Zollner EW, Willemse M, Hesseling AC, Magdorf K, Schaaf HS. Abnormal thyroid function tests in children on ethionamide treatment. Int J Tuberc Lung Dis 2011;15:1191-1193.
98. Hallbauer UM, Schaaf HS. Ethionamide-induced hypothyroidism in children. S Afr J Epidemiol Infect 2011;26:161-163.
99. Garazzino S, Tovo PA. Clinical experience with linezolid in infants and children. J Antimicrob Chemother 2011;66:iv23-iv41.
100. Barker RD, Millard FJ, Nthangeni ME. Unpaid community volunteers: effective providers of directly observed therapy (DOT) in rural South Africa. S Afr Med J 2002;92:291-294. (Pubitemid 34662444)
101. Clarke M, Dick J, Zwarenstein M, Lombard CJ, Diwan VK. Lay health worker intervention with choice of DOT superior to standard TB care for farm dwellers in South Africa: a cluster randomised control trial. Int J Tuberc Lung Dis 2005;9:673-679. (Pubitemid 40826161)
102. Farmer P, Kim JY. Community based approaches to the control of multidrug resistant tuberculosis: introducing "Dots-plus". BMJ 1998;317:671-674. (Pubitemid 28403501)
103. Weber HC, Beyers N, Gie RP, Schaaf HS, Fish T, Donald PR. The clinical and radiological features of tuberculosis in adolescents. Ann Trop Paediatr 2000;20:5-10. (Pubitemid 30171221)
104. Taken your medicine? The Economist. Technology Quarterly, Q2 2009,7-8.
105. Schaaf HS, Marais BJ, Hesseling AC, Brittle W, Donald PR. Surveillance of antituberculosis drug resistance among children from the Western Cape Province of South Africa: an upward trend. Am J Public Health 2009;99:1486-1490.
106. Schaaf HS, Marais BJ, Hesseling AC, Gie RP, Beyers N, Donald PR. Childhood drug-resistant tuberculosis in the Western Cape Province of South Africa. Acta Paediatr 2006;95:523-528. (Pubitemid 43791572)
107. Matlow A, Robb M, Goldman C. Infection control and paediatric tuberculosis: a practical guide for the practicing paediatrician. Paediatr Child Health (Oxford) 2003;8:624-626. (Pubitemid 38101291)
108. Starke JR. Transmission of mycobacterium tuberculosis to and from children and adolescents. Semin Pediatr Infect Dis 2001;12:115-123. (Pubitemid 32396406)
109. Cruz AT, Starke JR. A current review of infection control for childhood tuberculosis. Tuberculosis (Edinb) 2011;91:S11-S15.
110. Barroso E, Mota R, Pinheiro V, Campelo C, Rodrigues J. Occurence of active tuberculosis in households inhabited by patients with susceptible and mulidrug-resistant tuberculosis. J Bras Pneumol 2004;30:401-408.
111. Snider DE Jr, Kelly GD, Cauthen GM, Thompson NJ, Kilburn JO. Infection and disease among contacts of tuberculosis cases with drug-resistant and drug-susceptible bacilli. Am Rev Respir Dis 1985;132:125-132. (Pubitemid 15026199)
112. Teixeira L, Perkins MD, Johnson JL, Keller R, Palaci M, do Valle Dettoni V, Canedo Rocha LM, Debanne S, Talbot E, Dietze R. Infection and disease among household contacts of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2001;5:321-328. (Pubitemid 32397582)
113. Schaaf HS, Gie RP, Kennedy M, Beyers N, Hesseling PB, Donald PR. Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up. Pediatrics 2002;109:765-771. (Pubitemid 34493340)
114. Risk of tuberculosis among contacts of isoniazid-resistant and isoniazid-susceptible cases. Int J Tuberc Lung Dis 2011;15:782-788.
115. Centers for Disease Control and Prevention. Guidelines for preventing the transmission of mycobacterium tuberculosis in health-care settings, 2005. MMWR 2005;54(Rr-17).
116. World Health Organization. WHO policy on TB infection control in health-care facilities, congregate settings and households [accessed 2012 Jul 12]. WHO/HTM/TB/2009.419. Available from: http://whqlibdoc.Who.Int/publications/ 2009/9789241598323-eng.Pdf
117. Schaaf HS, Krook S, Hollemans DW, Warren RM, Donald PR, Hesseling AC. Recurrent culture-confirmed tuberculosis in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2005; 24:685-691. (Pubitemid 41140950)
118. Granich RM, Oh P, Lewis B, Porco TC, Flood J. Multidrug resistance among persons with tuberculosis in California, 1994-2003. JAMA 2005;293:2732-2739. (Pubitemid 40965085)
119. van der Watt JJ, Harrison TB, Benatar M, Heckmann JM. Polyneuropathy, anti-tuberculosis treatment and the role of pyridoxine in the HIV/AIDS era: a systematic review. Int J Tuberc Lung Dis 2011;15:722-728.
120. Vega P, Sweetland A, Acha J, Castillo H, Guerra D, Smith Fawzi MC, Shin S. Psychiatric issues in the management of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2004;8:749-759. (Pubitemid 38747152)
121. Ziganshina LE, Squire SB. Fluoroquinolones for treating tuberculosis. Cochrane Database Syst Rev 2008: CD004795.
122. Meissner HC, Townsend T,Wenman W, Kaplan SL, Morfin MR, Edge-Padbury B, Naberhuis-Stehouwer S, Bruss JB. Hematologic effects of linezolid in young children. Pediatr Infect Dis J 2003;22:S186-S192. (Pubitemid 37158768)